Ironwood Pharmaceuticals (IRWD) : Traders are bullish on Ironwood Pharmaceuticals (IRWD) as it has outperformed the S&P 500 by a wide margin of 3.91% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.8% in the last 1 week, and is up 8.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 6.07% and the 50-Day Moving Average is 11.54%.
Ironwood Pharmaceuticals (NASDAQ:IRWD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $12.70 and $12.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $13.76. The buying momentum continued till the end and the stock did not give up its gains. It closed at $13.61, notching a gain of 8.45% for the day. The total traded volume was 2,694,026 . The stock had closed at $12.55 on the previous day.
The company Insiders own 7.17% of Ironwood Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -6.38% . Institutional Investors own 97.06% of Ironwood Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of 8.25%. In a related news, The director, of Ironwood Pharmaceuticals Inc, Olanoff Lawrence S had unloaded 2,200 shares at $12.92 per share in a transaction on June 3, 2016. The total value of transaction was $28,424. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.